{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:11:40Z","timestamp":1791357100400,"version":"4.3.1"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Gen Hosp Psychiatry"],"DOI":"10.1186\/1475-2832-3-4","type":"journal-article","created":{"date-parts":[[2004,2,25]],"date-time":"2004-02-25T07:22:06Z","timestamp":1077693726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Off-label indications for atypical antipsychotics: A systematic review"],"prefix":"10.1186","volume":"3","author":[{"given":"Konstantinos N","family":"Fountoulakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Nimatoudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Iacovides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kaprinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,2,18]]},"reference":[{"key":"172_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2165\/00023210-199809030-00005","volume":"9","author":"MN Potenza","year":"1998","unstructured":"Potenza MN, McDougle CJ: Potential of Atypical Antipsychotics in the Treatment of NonPsychotic Disorders. CNS Drugs. 1998, 9: 213-232.","journal-title":"CNS Drugs"},{"key":"172_CR2","first-page":"1","volume-title":"International Clinical Psychopharmacology","author":"I Schweitzer","year":"2001","unstructured":"Schweitzer I: Does Risperidone have a place in the treatment of nonschizophrenic patients?. International Clinical Psychopharmacology. 2001, 1-19. 10.1097\/00004850-200101000-00001."},{"key":"172_CR3","first-page":"5","volume":"55 suppl","author":"JE Leysen","year":"1994","unstructured":"Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. Journal of Clinical Psychiatry. 1994, 55 suppl: 5-12.","journal-title":"Journal of Clinical Psychiatry"},{"key":"172_CR4","first-page":"25","volume-title":"Journal of Clinical Psychopharmacology","author":"G Chouinard","year":"1993","unstructured":"Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, W Arnot: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology. 1993, 25-40."},{"key":"172_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1176\/ajp.151.6.825","volume":"151","author":"SR Marder","year":"1994","unstructured":"Marder SR, Meilbach RC: Risperidone in the treatment of Schizophrenia. American Journal of Psychiatry. 1994, 151: 825-835.","journal-title":"American Journal of Psychiatry"},{"key":"172_CR6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","volume":"158","author":"S Kapur","year":"2001","unstructured":"Kapur S, Seeman P: Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis. American Journal of Psychiatry. 2001, 158: 360-369. 10.1176\/appi.ajp.158.3.360.","journal-title":"American Journal of Psychiatry"},{"key":"172_CR7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","volume":"156","author":"S Kapur","year":"1999","unstructured":"Kapur S, Zipursky RB, Remington G: Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia. American Journal of Psychiatry. 1999, 156: 286-293.","journal-title":"American Journal of Psychiatry"},{"key":"172_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"A Jadad","year":"1996","unstructured":"Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials. 1996, 17: 1-12. 10.1016\/0197-2456(95)00134-4.","journal-title":"Controlled Clinical Trials"},{"key":"172_CR9","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/070674370004500407","volume":"45","author":"Y Ad-Dab'bagh","year":"2000","unstructured":"Ad-Dab'bagh Y, Greenfield B, Milne-Smith J, Freedman H: Inpatient treatment of severe disruptive behaviour disorders with risperidone and milieu therapy. Can J Psychiatry. 2000, 45: 376-382.","journal-title":"Can J Psychiatry"},{"key":"172_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4088\/JCP.v59n0509c","volume":"59","author":"C Andrade","year":"1998","unstructured":"Andrade C: Risperidone may worsen fluoxetine-treated OCD. J Clin Psychiatry. 1998, 59: 255-256.","journal-title":"J Clin Psychiatry"},{"key":"172_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/00004714-199606000-00015","volume":"16","author":"JA Bourgeois","year":"1996","unstructured":"Bourgeois JA, Klein M: Risperidone and fluoxetine in the treatment of pedophilia with comorbid dysthymia. J Clin Psychopharmacol. 1996, 16: 257-258. 10.1097\/00004714-199606000-00015.","journal-title":"J Clin Psychopharmacol"},{"key":"172_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4088\/JCP.v62n0111","volume":"62","author":"R Bruggeman","year":"2001","unstructured":"Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA: Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry. 2001, 62: 50-56.","journal-title":"J Clin Psychiatry"},{"key":"172_CR13","first-page":"29","volume":"57","author":"RD Bruun","year":"1996","unstructured":"Bruun RD, Budman CL: Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry. 1996, 57: 29-31.","journal-title":"J Clin Psychiatry"},{"key":"172_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/cap.2000.10.19","volume":"10","author":"JK Buitelaar","year":"2000","unstructured":"Buitelaar JK: Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol. 2000, 10: 19-26.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4088\/JCP.v62n0405","volume":"62","author":"JK Buitelaar","year":"2001","unstructured":"Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT: A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001, 62: 239-248.","journal-title":"J Clin Psychiatry"},{"key":"172_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1023\/A:1025926817928","volume":"29","author":"NA Dartnall","year":"1999","unstructured":"Dartnall NA, Holmes JP, Morgan SN, McDougle CJ: Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism. J Autism Dev Disord. 1999, 29: 87-91. 10.1023\/A:1025926817928.","journal-title":"J Autism Dev Disord"},{"key":"172_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/cap.1996.6.79","volume":"6","author":"HB Demb","year":"1996","unstructured":"Demb HB: Risperidone in young children with pervasive developmental disorders and other developmental disabilities. J Child Adolesc Psychopharmacol. 1996, 6: 79-80.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR18","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/070674379804301017","volume":"43","author":"RJ Doan","year":"1998","unstructured":"Doan RJ: Risperidone for insomnia in PDDs. Can J Psychiatry. 1998, 43: 1050-1051.","journal-title":"Can J Psychiatry"},{"key":"172_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/cap.1996.6.139","volume":"6","author":"RC Dryden-Edwards","year":"1996","unstructured":"Dryden-Edwards RC, Reiss AL: Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. J Child Adolesc Psychopharmacol. 1996, 6: 139-145.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/1520-6394(2000)11:4<187::AID-DA9>3.0.CO;2-C","volume":"11","author":"I Eidelman","year":"2000","unstructured":"Eidelman I, Seedat S, Stein DJ: Risperidone in the treatment of acute stress disorder in physically traumatized in-patients. Depress Anxiety. 2000, 11: 187-188. 10.1002\/1520-6394(2000)11:4<187::AID-DA9>3.3.CO;2-3.","journal-title":"Depress Anxiety"},{"key":"172_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1089\/cap.1999.9.43","volume":"9","author":"CN Epperson","year":"1999","unstructured":"Epperson CN, Fasula D, Wasylink S, Price LH, McDougle CJ: Risperidone addition in serotonin reuptake inhibitor-resistant trichotillomania: three cases. J Child Adolesc Psychopharmacol. 1999, 9: 43-49.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/cap.1996.6.177","volume":"6","author":"S Fisman","year":"1996","unstructured":"Fisman S, Steele M: Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol. 1996, 6: 177-190.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1089\/cap.1999.9.115","volume":"9","author":"KD Fitzgerald","year":"1999","unstructured":"Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR: Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol. 1999, 9: 115-123.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/070674370104600313","volume":"46","author":"A Gabriel","year":"2001","unstructured":"Gabriel A: A case of resistant trichotillomania treated with risperidone-augmented fluvoxamine. Can J Psychiatry. 2001, 46: 285-286.","journal-title":"Can J Psychiatry"},{"key":"172_CR25","first-page":"1097","volume":"152","author":"WJ Giakas","year":"1995","unstructured":"Giakas WJ: Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder. Am J Psychiatry. 1995, 152: 1097-1098.","journal-title":"Am J Psychiatry"},{"key":"172_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00004714-200006000-00003","volume":"20","author":"J Grabowski","year":"2000","unstructured":"Grabowski J, Rhoades H, Silverman P, Schmitz JM, Stotts A, Creson D, Bailey R: Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. Journal of Clinical Psychopharmacology. 2000, 20: 305-310. 10.1097\/00004714-200006000-00003.","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"172_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1089\/cap.1999.9.277","volume":"9","author":"GL Hanna","year":"1999","unstructured":"Hanna GL, Fluent TE, Fischer DJ: Separation anxiety in children and adolescents treated with risperidone. J Child Adolesc Psychopharmacol. 1999, 9: 277-283.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR28","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1097\/00004583-199611000-00025","volume":"35","author":"A Hardan","year":"1996","unstructured":"Hardan A, Johnson K, Johnson C, Hrecznyj B: Case study: risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry. 1996, 35: 1551-1556. 10.1097\/00004583-199611000-00025.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"172_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1046\/j.1440-1819.2001.00805.x","volume":"55","author":"S Hirose","year":"2001","unstructured":"Hirose S: Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psychiatry Clin Neurosci. 2001, 55: 161-162. 10.1046\/j.1440-1819.2001.00805.x.","journal-title":"Psychiatry Clin Neurosci"},{"key":"172_CR30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1023\/A:1025854532079","volume":"27","author":"JP Horrigan","year":"1997","unstructured":"Horrigan JP, Barnhill LJ: Risperidone and explosive aggressive autism. J Autism Dev Disord. 1997, 27: 313-323. 10.1023\/A:1025854532079.","journal-title":"J Autism Dev Disord"},{"key":"172_CR31","first-page":"423","volume":"56","author":"FM Jacobsen","year":"1995","unstructured":"Jacobsen FM: Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry. 1995, 56: 423-429.","journal-title":"J Clin Psychiatry"},{"key":"172_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1046\/j.1440-1819.2000.00760.x","volume":"54","author":"T Kawahara","year":"2000","unstructured":"Kawahara T, Ueda Y, Mitsuyama Y: A case report of refractory obsessive-compulsive disorder improved by risperidone augmentation of clomipramine treatment. Psychiatry Clin Neurosci. 2000, 54: 599-601. 10.1046\/j.1440-1819.2000.00760.x.","journal-title":"Psychiatry Clin Neurosci"},{"key":"172_CR33","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/00005053-199705000-00011","volume":"185","author":"HR Khouzam","year":"1997","unstructured":"Khouzam HR, Donnelly NJ: Remission of self-mutilation in a patient with borderline personality during risperidone therapy. J Nerv Ment Dis. 1997, 185: 348-349. 10.1097\/00005053-199705000-00011.","journal-title":"J Nerv Ment Dis"},{"key":"172_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1055\/s-2001-18610","volume":"28","author":"U Knopf","year":"2001","unstructured":"Knopf U, Hubrich-Ungureanu P, Thome J: [Paroxetine augmentation with risperidone in therapy-resistant depression]. Psychiatr Prax. 2001, 28: 405-406. 10.1055\/s-2001-18610.","journal-title":"Psychiatr Prax"},{"key":"172_CR35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/milmed\/164.8.605","volume":"164","author":"D Krashin","year":"1999","unstructured":"Krashin D, Oates EW: Risperidone as an adjunct therapy for post-traumatic stress disorder. Mil Med. 1999, 164: 605-606.","journal-title":"Mil Med"},{"key":"172_CR36","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1097\/00004583-199509000-00011","volume":"34","author":"PJ Lombroso","year":"1995","unstructured":"Lombroso PJ, Scahill L, King RA, Lynch KA, Chappell PB, Peterson BS, McDougle CJ, Leckman JF: Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry. 1995, 34: 1147-1152.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"172_CR37","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S0010-440X(99)90132-3","volume":"40","author":"GA Maguire","year":"1999","unstructured":"Maguire GA, Gottschalk LA, Riley GD, Franklin DL, Bechtel RJ, Ashurst J: Stuttering: neuropsychiatric features measured by content analysis of speech and the effect of risperidone on stuttering severity. Compr Psychiatry. 1999, 40: 308-314.","journal-title":"Compr Psychiatry"},{"key":"172_CR38","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1097\/00004583-200110000-00015","volume":"40","author":"G Masi","year":"2001","unstructured":"Masi G, Cosenza A, Mucci M, Brovedani P: Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2001, 40: 1206-1214. 10.1097\/00004583-200110000-00015.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"172_CR39","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/088307380101600602","volume":"16","author":"G Masi","year":"2001","unstructured":"Masi G, Cosenza A, Mucci M, De Vito G: Risperidone monotherapy in preschool children with pervasive developmental disorders. J Child Neurol. 2001, 16: 395-400.","journal-title":"J Child Neurol"},{"key":"172_CR40","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","volume":"57","author":"CJ McDougle","year":"2000","unstructured":"McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000, 57: 794-801. 10.1001\/archpsyc.57.8.794.","journal-title":"Arch Gen Psychiatry"},{"key":"172_CR41","first-page":"526","volume":"56","author":"CJ McDougle","year":"1995","unstructured":"McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH: Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry. 1995, 56: 526-528.","journal-title":"J Clin Psychiatry"},{"key":"172_CR42","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/archpsyc.55.7.633","volume":"55","author":"CJ McDougle","year":"1998","unstructured":"McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH: A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry. 1998, 55: 633-641. 10.1001\/archpsyc.55.7.633.","journal-title":"Arch Gen Psychiatry"},{"key":"172_CR43","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/00002826-200011000-00007","volume":"23","author":"C Miodownik","year":"2000","unstructured":"Miodownik C, Lerner V: Risperidone in the treatment of psychotic depression. Clin Neuropharmacol. 2000, 23: 335-337. 10.1097\/00002826-200011000-00007.","journal-title":"Clin Neuropharmacol"},{"key":"172_CR44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/00004714-199908000-00016","volume":"19","author":"EP Monnelly","year":"1999","unstructured":"Monnelly EP, Ciraulo DA: Risperidone effects on irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol. 1999, 19: 377-378. 10.1097\/00004714-199908000-00016.","journal-title":"J Clin Psychopharmacol"},{"key":"172_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0165-1781(01)00255-4","volume":"102","author":"TF Newton","year":"2001","unstructured":"Newton TF, Ling W, Kalechstein AD, Uslaner J, Tervo K: Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Research. 2001, 102: 227-233. 10.1016\/S0165-1781(01)00255-4.","journal-title":"Psychiatry Research"},{"key":"172_CR46","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/00004583-199804000-00014","volume":"37","author":"R Nicolson","year":"1998","unstructured":"Nicolson R, Awad G, Sloman L: An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry. 1998, 37: 372-376. 10.1097\/00004583-199804000-00014.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"172_CR47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00004714-199802000-00018","volume":"18","author":"M O'Connor","year":"1998","unstructured":"O'Connor M, Silver H: Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. J Clin Psychopharmacol. 1998, 18: 89-91. 10.1097\/00004714-199802000-00018.","journal-title":"J Clin Psychopharmacol"},{"key":"172_CR48","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4088\/JCP.v60n0410","volume":"60","author":"RB Ostroff","year":"1999","unstructured":"Ostroff RB, Nelson JC: Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999, 60: 256-259.","journal-title":"J Clin Psychiatry"},{"key":"172_CR49","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/cap.1997.7.167","volume":"7","author":"R Perry","year":"1997","unstructured":"Perry R, Pataki C, Munoz-Silva DM, Armenteros J, Silva RR: Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol. 1997, 7: 167-179.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR50","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/00004850-200015050-00007","volume":"15","author":"C Pfanner","year":"2000","unstructured":"Pfanner C, Marazziti D, Dell'Osso L, Presta S, Gemignani A, Milanfranchi A, Cassano GB: Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol. 2000, 15: 297-301.","journal-title":"Int Clin Psychopharmacol"},{"key":"172_CR51","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/cap.1999.9.273","volume":"9","author":"DJ Posey","year":"1999","unstructured":"Posey DJ, Walsh KH, Wilson GA, McDougle CJ: Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol. 1999, 9: 273-276.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR52","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/070674379403900703","volume":"39","author":"SE Purdon","year":"1994","unstructured":"Purdon SE, Lit W, Labelle A, Jones BD: Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry. 1994, 39: 400-405.","journal-title":"Can J Psychiatry"},{"key":"172_CR53","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/089198879500800303","volume":"8","author":"RK Raheja","year":"1995","unstructured":"Raheja RK, Bharwani I, Penetrante AE: Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation. J Geriatr Psychiatry Neurol. 1995, 8: 159-161.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"172_CR54","first-page":"677","volume":"32","author":"L Ravizza","year":"1996","unstructured":"Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G: Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull. 1996, 32: 677-682.","journal-title":"Psychopharmacol Bull"},{"key":"172_CR55","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/00004714-200012000-00025","volume":"20","author":"P Sandor","year":"2000","unstructured":"Sandor P, Stephens RJ: Risperidone treatment of aggressive behavior in children with Tourette syndrome. J Clin Psychopharmacol. 2000, 20: 710-712. 10.1097\/00004714-200012000-00025.","journal-title":"J Clin Psychopharmacol"},{"key":"172_CR56","first-page":"303","volume":"57","author":"S Saxena","year":"1996","unstructured":"Saxena S, Wang D, Bystritsky A, Baxter L. R., Jr.: Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry. 1996, 57: 303-306.","journal-title":"J Clin Psychiatry"},{"key":"172_CR57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/cap.1998.8.49","volume":"8","author":"HA Schreier","year":"1998","unstructured":"Schreier HA: Risperidone for young children with mood disorders and aggressive behavior. J Child Adolesc Psychopharmacol. 1998, 8: 49-59.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR58","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/1520-6394(2000)11:4<185::AID-DA8>3.0.CO;2-H","volume":"11","author":"S Seedat","year":"2000","unstructured":"Seedat S, Kesler S, Niehaus DJ, Stein DJ: Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety. 2000, 11: 185-186. 10.1002\/1520-6394(2000)11:4<185::AID-DA8>3.3.CO;2-8.","journal-title":"Depress Anxiety"},{"key":"172_CR59","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1177\/070674379704200920","volume":"42","author":"DA Smelson","year":"1997","unstructured":"Smelson DA, Roy A, Roy M: Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients. Can J Psychiatry. 1997, 42: 984-","journal-title":"Can J Psychiatry"},{"key":"172_CR60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4088\/JCP.v58n0306","volume":"58","author":"DJ Stein","year":"1997","unstructured":"Stein DJ, Bouwer C, Hawkridge S, Emsley RA: Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry. 1997, 58: 119-122.","journal-title":"J Clin Psychiatry"},{"key":"172_CR61","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/00004714-200008000-00020","volume":"20","author":"AL Stoll","year":"2000","unstructured":"Stoll AL, Haura G: Tranylcypromine plus risperidone for treatment-refractory major depression. J Clin Psychopharmacol. 2000, 20: 495-496. 10.1097\/00004714-200008000-00020.","journal-title":"J Clin Psychopharmacol"},{"key":"172_CR62","first-page":"587","volume":"24","author":"TF Sun","year":"2001","unstructured":"Sun TF, Lin PY, Wu CK: Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases. Chang Gung Med J. 2001, 24: 587-592.","journal-title":"Chang Gung Med J"},{"key":"172_CR63","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/104454601750143348","volume":"11","author":"M Van Bellinghen","year":"2001","unstructured":"Van Bellinghen M, De Troch C: Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol. 2001, 11: 5-13. 10.1089\/104454601750143348.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR64","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/mds.870090617","volume":"9","author":"C van der Linden","year":"1994","unstructured":"van der Linden C, Bruggeman R, van Woerkom TC: Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: an open pilot dose-titration study with risperidone. Mov Disord. 1994, 9: 687-688.","journal-title":"Mov Disord"},{"key":"172_CR65","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/070674370104600614","volume":"46","author":"F Vercellino","year":"2001","unstructured":"Vercellino F, Zanotto E, Ravera G, Veneselli E: Open-label risperidone treatment of 6 children and adolescents with autism. Can J Psychiatry. 2001, 46: 559-560.","journal-title":"Can J Psychiatry"},{"key":"172_CR66","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/cap.2000.10.79","volume":"10","author":"A Zuddas","year":"2000","unstructured":"Zuddas A, Di Martino A, Muglia P, Cianchetti C: Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol. 2000, 10: 79-90.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR67","first-page":"155","volume":"33","author":"RL Findling","year":"1997","unstructured":"Findling RL, Maxwell K, Wiznitzer M: An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacology Bulletin. 1997, 33: 155-159.","journal-title":"Psychopharmacology Bulletin"},{"key":"172_CR68","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s001150050402","volume":"70","author":"M Adli","year":"1999","unstructured":"Adli M, Rossius W, Bauer M: [Olanzapine in the treatment of depressive disorders with psychotic symptoms]. Nervenarzt. 1999, 70: 68-71. 10.1007\/s001150050402.","journal-title":"Nervenarzt"},{"key":"172_CR69","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1176\/appi.ajp.158.11.1929-a","volume":"158","author":"AK Ashton","year":"2001","unstructured":"Ashton AK: Olanzapine augmentation for trichotillomania. Am J Psychiatry. 2001, 158: 1929-1930. 10.1176\/appi.ajp.158.11.1929-a.","journal-title":"Am J Psychiatry"},{"key":"172_CR70","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1176\/appi.ajp.159.1.155","volume":"159","author":"F Benazzi","year":"2002","unstructured":"Benazzi F: Fluoxetine and Olanzapine for Resistant Depression. Am J Psychiatry. 2002, 159: 155-10.1176\/appi.ajp.159.1.155.","journal-title":"Am J Psychiatry"},{"key":"172_CR71","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1192\/bjp.172.4.366a","volume":"172","author":"BR Bhadrinath","year":"1998","unstructured":"Bhadrinath BR: Olanzapine in Tourette syndrome. Br J Psychiatry. 1998, 172: 366-","journal-title":"Br J Psychiatry"},{"key":"172_CR72","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0165-1781(00)00203-1","volume":"96","author":"F Bogetto","year":"2000","unstructured":"Bogetto F, Bellino S, Vaschetto P, Ziero S: Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res. 2000, 96: 91-98. 10.1016\/S0165-1781(00)00203-1.","journal-title":"Psychiatry Res"},{"key":"172_CR73","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4088\/JCP.v62n0412","volume":"62","author":"CL Budman","year":"2001","unstructured":"Budman CL, Gayer A, Lesser M, Shi Q, Bruun RD: An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. J Clin Psychiatry. 2001, 62: 290-294.","journal-title":"J Clin Psychiatry"},{"key":"172_CR74","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/00004850-200107000-00003","volume":"16","author":"MI Butterfield","year":"2001","unstructured":"Butterfield MI, Becker ME, Connor KM, Sutherland S, Churchill LE, Davidson JR: Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol. 2001, 16: 197-203. 10.1097\/00004850-200107000-00003.","journal-title":"Int Clin Psychopharmacol"},{"key":"172_CR75","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/070674370104600408","volume":"46","author":"G Francobandiera","year":"2001","unstructured":"Francobandiera G: Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry. 2001, 46: 356-358.","journal-title":"Can J Psychiatry"},{"key":"172_CR76","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/120347540000400310","volume":"4","author":"S Garnis-Jones","year":"2000","unstructured":"Garnis-Jones S, Collins S, Rosenthal D: Treatment of self-mutilation with olanzapine. J Cutan Med Surg. 2000, 4: 161-163.","journal-title":"J Cutan Med Surg"},{"key":"172_CR77","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1034\/j.1399-5618.2000.020307.x","volume":"2","author":"SN Ghaemi","year":"2000","unstructured":"Ghaemi SN, Cherry EL, Katzow JA, Goodwin FK: Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord. 2000, 2: 196-199. 10.1034\/j.1399-5618.2000.020109.x.","journal-title":"Bipolar Disord"},{"key":"172_CR78","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4088\/JCP.v62n0413e","volume":"62","author":"JE Grant","year":"2001","unstructured":"Grant JE: Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report. J Clin Psychiatry. 2001, 62: 297-298.","journal-title":"J Clin Psychiatry"},{"key":"172_CR79","first-page":"143","volume":"66","author":"MA Gupta","year":"2000","unstructured":"Gupta MA, Gupta AK: Olanzapine is effective in the management of some self-induced dermatoses: three case reports. Cutis. 2000, 66: 143-146.","journal-title":"Cutis"},{"key":"172_CR80","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s102270000019","volume":"5","author":"MA Gupta","year":"2001","unstructured":"Gupta MA, Gupta AK: Olanzapine may be an effective adjunctive therapy in the management of acne excoriee: a case report. J Cutan Med Surg. 2001, 5: 25-27.","journal-title":"J Cutan Med Surg"},{"key":"172_CR81","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1192\/S000712500026354X","volume":"175","author":"L Hansen","year":"1999","unstructured":"Hansen L: Olanzapine in the treatment of anorexia nervosa. Br J Psychiatry. 1999, 175: 592-","journal-title":"Br J Psychiatry"},{"key":"172_CR82","doi-asserted-by":"publisher","first-page":"296","DOI":"10.4088\/JCP.v62n0413d","volume":"62","author":"DW Hough","year":"2001","unstructured":"Hough DW: Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder. J Clin Psychiatry. 2001, 62: 296-297.","journal-title":"J Clin Psychiatry"},{"key":"172_CR83","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1192\/bjp.177.1.87","volume":"177","author":"VS Jensen","year":"2000","unstructured":"Jensen VS, Mejlhede A: Anorexia nervosa: treatment with olanzapine. Br J Psychiatry. 2000, 177: 87-10.1192\/bjp.177.1.87.","journal-title":"Br J Psychiatry"},{"key":"172_CR84","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1159\/000054886","volume":"43","author":"F Konig","year":"2001","unstructured":"Konig F, von Hippel C, Petersdorff T, Neuhoffer-Weiss M, Wolfersdorf M, Kaschka WP: First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression. Neuropsychobiology. 2001, 43: 170-174. 10.1159\/000054886.","journal-title":"Neuropsychobiology"},{"key":"172_CR85","doi-asserted-by":"publisher","first-page":"514","DOI":"10.4088\/JCP.v61n0709","volume":"61","author":"LM Koran","year":"2000","unstructured":"Koran LM, Ringold AL, Elliott MA: Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2000, 61: 514-517.","journal-title":"J Clin Psychiatry"},{"key":"172_CR86","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/cap.1998.8.107","volume":"8","author":"J Krishnamoorthy","year":"1998","unstructured":"Krishnamoorthy J, King BH: Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol. 1998, 8: 107-113.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR87","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/(SICI)1098-108X(200004)27:3<363::AID-EAT16>3.0.CO;2-5","volume":"27","author":"MC La Via","year":"2000","unstructured":"La Via MC, Gray N, Kaye WH: Case reports of olanzapine treatment of anorexia nervosa. Int J Eat Disord. 2000, 27: 363-366. 10.1002\/(SICI)1098-108X(200004)27:3<363::AID-EAT16>3.3.CO;2-X.","journal-title":"Int J Eat Disord"},{"key":"172_CR88","first-page":"667","volume":"45","author":"LA Labbate","year":"2000","unstructured":"Labbate LA, Douglas S: Olanzapine for nightmares and sleep disturbance in posttraumatic stress disorder (PTSD). Can J Psychiatry. 2000, 45: 667-668.","journal-title":"Can J Psychiatry"},{"key":"172_CR89","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/00004583-199809000-00006","volume":"37","author":"P Malek-Ahmadi","year":"1998","unstructured":"Malek-Ahmadi P, Simonds JF: Olanzapine for autistic disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1998, 37: 902-10.1097\/00004583-199809000-00006.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"172_CR90","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/00004583-200108000-00009","volume":"40","author":"RP Malone","year":"2001","unstructured":"Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA: Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry. 2001, 40: 887-894. 10.1097\/00004583-200108000-00009.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"172_CR91","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/10401230009147107","volume":"12","author":"LA Nelson","year":"2000","unstructured":"Nelson LA, Swartz CM: Melancholic symptoms during concurrent olanzapine and fluoxetine. Ann Clin Psychiatry. 2000, 12: 167-170. 10.1023\/A:1009021119654.","journal-title":"Ann Clin Psychiatry"},{"key":"172_CR92","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s004150070173","volume":"247","author":"M Onofrj","year":"2000","unstructured":"Onofrj M, Paci C, D'Andreamatteo G, Toma L: Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol. 2000, 247: 443-446. 10.1007\/s004150070173.","journal-title":"J Neurol"},{"key":"172_CR93","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/00004850-200111000-00003","volume":"16","author":"F Petty","year":"2001","unstructured":"Petty F, Brannan S, Casada J, Davis LL, Gajewski V, Kramer GL, Stone RC, Teten AL, Worchel J, Young KA: Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int Clin Psychopharmacol. 2001, 16: 331-337. 10.1097\/00004850-200111000-00003.","journal-title":"Int Clin Psychopharmacol"},{"key":"172_CR94","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1176\/appi.ajp.158.10.1737-a","volume":"158","author":"W Pitchot","year":"2001","unstructured":"Pitchot W, Ansseau M: Addition of olanzapine for treatment-resistant depression. Am J Psychiatry. 2001, 158: 1737-1738. 10.1176\/appi.ajp.158.10.1737-a.","journal-title":"Am J Psychiatry"},{"key":"172_CR95","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/00004714-199902000-00008","volume":"19","author":"MN Potenza","year":"1999","unstructured":"Potenza MN, Holmes JP, Kanes SJ, McDougle CJ: Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol. 1999, 19: 37-44. 10.1097\/00004714-199902000-00008.","journal-title":"J Clin Psychopharmacol"},{"key":"172_CR96","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1176\/ajp.155.9.1299a","volume":"155","author":"MN Potenza","year":"1998","unstructured":"Potenza MN, Wasylink S, Epperson CN, McDougle CJ: Olanzapine augmentation of fluoxetine in the treatment of trichotillomania. Am J Psychiatry. 1998, 155: 1299-1300.","journal-title":"Am J Psychiatry"},{"key":"172_CR97","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4088\/JCP.v60n0208","volume":"60","author":"AJ Rothschild","year":"1999","unstructured":"Rothschild AJ, Bates KS, Boehringer KL, Syed A: Olanzapine response in psychotic depression. J Clin Psychiatry. 1999, 60: 116-118.","journal-title":"J Clin Psychiatry"},{"key":"172_CR98","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/S0006-3223(99)00128-6","volume":"46","author":"SC Schulz","year":"1999","unstructured":"Schulz SC, Camlin KL, Berry SA, Jesberger JA: Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 1999, 46: 1429-1435. 10.1016\/S0006-3223(99)00128-6.","journal-title":"Biol Psychiatry"},{"key":"172_CR99","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1176\/appi.ajp.158.1.131","volume":"158","author":"RC Shelton","year":"2001","unstructured":"Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY: A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001, 158: 131-134. 10.1176\/appi.ajp.158.1.131.","journal-title":"Am J Psychiatry"},{"key":"172_CR100","first-page":"85","volume":"29","author":"J Soler","year":"2001","unstructured":"Soler J, Campins MJ, Perez V, Puigdemont D, Perez-Blanco E, Alvarez E: [Olanzapine and cognitive-behavioural group therapy in borderline personality disorder]. Actas Esp Psiquiatr. 2001, 29: 85-90.","journal-title":"Actas Esp Psiquiatr"},{"key":"172_CR101","first-page":"69","volume":"14","author":"F Squitieri","year":"2001","unstructured":"Squitieri F, Cannella M, Piorcellini A, Brusa L, Simonelli M, Ruggieri S: Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001, 14: 69-72.","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"172_CR102","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00004850-200015010-00003","volume":"15","author":"M Stamenkovic","year":"2000","unstructured":"Stamenkovic M, Schindler SD, Aschauer HN, De Zwaan M, Willinger U, Resinger E, Kasper S: Effective open-label treatment of tourette's disorder with olanzapine. Int Clin Psychopharmacol. 2000, 15: 23-28.","journal-title":"Int Clin Psychopharmacol"},{"key":"172_CR103","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3109\/10401239709147807","volume":"9","author":"RH Weisler","year":"1997","unstructured":"Weisler RH, Ahearn EP, Davidson JR, Wallace CD: Adjunctive use of olanzapine in mood disorders: five case reports. Ann Clin Psychiatry. 1997, 9: 259-262. 10.1023\/A:1022312612221.","journal-title":"Ann Clin Psychiatry"},{"key":"172_CR104","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4088\/JCP.v62n1103","volume":"62","author":"MC Zanarini","year":"2001","unstructured":"Zanarini MC, Frankenburg FR: Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001, 62: 849-854.","journal-title":"J Clin Psychiatry"},{"key":"172_CR105","first-page":"55","volume":"26","author":"A Khullar","year":"2001","unstructured":"Khullar A, Chue P, Tibbo P: Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci. 2001, 26: 55-59.","journal-title":"J Psychiatry Neurosci"},{"key":"172_CR106","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1089\/cap.1999.9.99","volume":"9","author":"A Martin","year":"1999","unstructured":"Martin A, Koenig K, Scahill L, Bregman J: Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 1999, 9: 99-107.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR107","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/104454601750284153","volume":"11","author":"D Padla","year":"2001","unstructured":"Padla D: Quetiapine resolves psychotic depression in an adolescent boy. J Child Adolesc Psychopharmacol. 2001, 11: 207-208. 10.1089\/104454601750284153.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR108","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/104454601750284108","volume":"11","author":"HC Parraga","year":"2001","unstructured":"Parraga HC, Parraga MI, Woodward RL, Fenning PA: Quetiapine treatment of children with Tourette's syndrome: report of two cases. J Child Adolesc Psychopharmacol. 2001, 11: 187-191. 10.1089\/104454601750284108.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"172_CR109","volume-title":"Diagnostic and Statistical Manual of Mental Disorder, 4th Edition","author":"APA","year":"1994","unstructured":"APA: Diagnostic and Statistical Manual of Mental Disorder, 4th Edition. 1994, Washington DC, American Psychiatric Press"},{"key":"172_CR110","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/archpsyc.1989.01810080052006","volume":"46","author":"E Shapiro","year":"1989","unstructured":"Shapiro E, Shapiro AK,, Fulop G: Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Archives of General Psychiatry. 1989, 46: 722-730.","journal-title":"Archives of General Psychiatry"},{"key":"172_CR111","first-page":"317","volume-title":"American Journal of Psychiatry","author":"ED Caine","year":"1979","unstructured":"Caine ED, Polinsky RJ, Kartzinel R: The trial use of clozapine for abnormal involuntary movement disorders. American Journal of Psychiatry. 1979, 317-320."},{"key":"172_CR112","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1176\/ajp.141.10.1195","volume":"141","author":"LT Anderson","year":"1984","unstructured":"Anderson LT, Cambell M, Grega DM, Perry R, Small AM, Green WH: Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. American Journal of Psychiatry. 1984, 141: 1195-1202.","journal-title":"American Journal of Psychiatry"},{"key":"172_CR113","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1176\/ajp.149.3.363","volume":"149","author":"CT Gordon","year":"1992","unstructured":"Gordon CT, Rapoport JL, Hamburger SD, State RC, Mannheim GB: Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry. 1992, 149: 363-366.","journal-title":"American Journal of Psychiatry"},{"key":"172_CR114","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/archpsyc.1993.01820180039004","volume":"50","author":"CT Gordon","year":"1993","unstructured":"Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL: A double-blind comparison of clomipramine, desipramine and placebo in the treatment of autistic disorder. Archives of General Psychiatry. 1993, 50: 441-447.","journal-title":"Archives of General Psychiatry"},{"key":"172_CR115","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/archpsyc.1996.01830110037005","volume":"53","author":"CJ McDougle","year":"1996","unstructured":"McDougle CJ, Naylor ST, Cohen DJ, FV Volkmar, Heninger GR, LH Price: A double-blind placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry. 1996, 53: 1001-1008.","journal-title":"Archives of General Psychiatry"},{"key":"172_CR116","first-page":"39","volume-title":"Drug Development Research","author":"TF Meert","year":"1992","unstructured":"Meert TF, PAJ Janssen: Ritanserin: a new therapeutic approach for drug abuse. Part 2: effects on cocaine. Drug Development Research. 1992, 39-53."},{"key":"172_CR117","first-page":"57","volume-title":"Psychopharmacology (Berlin)","author":"A Schotte","year":"1996","unstructured":"Schotte A, Janssen PMF, Gommeren W, Luyten WHML, VanGompel P, Lesage AS, DeLoore K, Leysen J: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berlin). 1996, 57-73."},{"key":"172_CR118","first-page":"302","volume-title":"American Journal of Psychiatry","author":"CJ McDougle","year":"1990","unstructured":"McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR: Haloperidol addition in fluvoxamine-refractory obssessive-compulsive disorder: a double-blind placebo-controlled study in patients with and without tics. American Journal of Psychiatry. 1990, 302-308."},{"key":"172_CR119","first-page":"250","volume-title":"Neuropsychopharmacology","author":"W Zhang","year":"2000","unstructured":"Zhang W, Perry WK, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP: Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on neorepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000, 250-262. 10.1016\/S0893-133X(00)00119-6."},{"key":"172_CR120","first-page":"148","volume-title":"Journal of Clinical Psychiatry","author":"NF Leone","year":"1982","unstructured":"Leone NF: Response of borderline patients to loxapine and chlorpromazine. Journal of Clinical Psychiatry. 1982, 148-150."},{"key":"172_CR121","first-page":"238","volume-title":"Journal of Clinical Psychopharmacology","author":"PH Soloff","year":"1989","unstructured":"Soloff PH, George A, Nathan RS: Amitriptyline versus haloperidol in borderlines: final outcome and predictors of response. Journal of Clinical Psychopharmacology. 1989, 238-246."}],"container-title":["Annals of General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1475-2832-3-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T16:09:54Z","timestamp":1726243794000},"score":1,"resource":{"primary":{"URL":"https:\/\/annals-general-psychiatry.biomedcentral.com\/articles\/10.1186\/1475-2832-3-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2,18]]},"references-count":121,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,12]]}},"alternative-id":["172"],"URL":"https:\/\/doi.org\/10.1186\/1475-2832-3-4","relation":{},"ISSN":["1475-2832"],"issn-type":[{"value":"1475-2832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2,18]]},"assertion":[{"value":"30 January 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"4"}}